• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

NYC Mortality From 1918 Flu Pandemic, COVID-19 'Comparable,' Say Researchers

Article

Excess deaths associated with the two pandemics are in the same ballpark during New York City peaks.

The excess mortality in New York City during the peak of the 1918 flu pandemic and the excess mortality during the early months of the COVID-19 pandemic were similar, according to a brief research report published in today’s JAMA Network Open.

During the peak months of the 1918 flu epidemic, there were 31,589 deaths from all causes among the city’s 5.5 million residents, according to Jeremy Samuel Faust, M.D., M.S., at Brigham and Women’s Hospital, and his colleagues, Zhenqiu Lin, Ph.D., at Yale-New Haven Hospital, and Carlos de Rio, M.D., at the Emory University School of Medicine.

That works out to 287.17 deaths per 100,000 person-months.

During the early phase of the COVID-19 outbreak in the city, between March 11 and May 11, there were 33,465 deaths from all causes among the 8.3 million residents, Faust and his colleagues calculated

That works out to 202.08 deaths per 100,000 person-months, so a lower proportion than the one for the 1918 flu epidemic peak period but still in the same ballpark.

“These findings suggest that the mortality associated with COVID-19 during the early phase of the New York City outbreak was comparable to the peak mortality observed during the 1918 H1N1 influence epidemic,” the researchers wrote.

But when Faust and his colleagues compared the peak periods of the two pandemics in New York City to baseline mortality rates in the preceding years, they found that the COVID-19 spike is higher relative to the 1918 spike. The peak mortality of the 1918 flu was about three times higher than the mortality in preceding years, whereas the peak COVID-19 mortality was four times higher than in the preceding years.

The research team used CDC data from 1914-18 to calculate the the figures for the 1918 flu pandemic. To developed the numbers for COVID-19, they sifted through data from the New York City Department of Health and Mental Hygiene and the U.S. Census Bureau.

Faust, Lin and de Rio said their study can’t address the question whether the 1918 H1N1 flu virus was more or less “naturally” virulent — that is, more or less likely to cause death or harm — than SARS-CoV-2, the virus that causes COVID-19. To make that comparison, they said, you’d have to know how many COVID-19 deaths have been averted by 21st century treatment advances that didn’t exist in the early 20th century.

The estimates vary, but the CDC says that the 1918 flu pandemic caused at least 50 million deaths worldwide and 675,000 deaths in the U.S. Using those figures, about 1.3% of the 1918 flu pandemic deaths were American deaths.

The COVID-19 count on the John Hopkins Coronavirus Resource Center this morning was 750,371 deaths worldwide and 166,118 in the U.S. Using that tally, 22% of the COVID-19 deaths so far have been American deaths.

Related Videos
Video 4 - "Diabetes Prevention and Reducing Disparities Across Populations"
Video 3 - "Integrating CGMs into Diabetes Treatment Programs"
Video 2 - "Identifying Inequities in CGM Access"
Video 1 - "Challenges in Treating High-Risk Patients With Diabetes"
Video 17 - "Insights on Plan Enhancements & Fertility Care Innovations"
Video 16 - "Mitigating Risks: How Fertility Benefits Safeguard Employee Health"
Video 15 - "Strategic Investment: Fertility Benefits and Positive Employee Outcomes"
"Supporting Employee Wellbeing Through Fertility Benefits"
Related Content
© 2024 MJH Life Sciences

All rights reserved.